论文部分内容阅读
目的分析急性脑梗死治疗中尤瑞克林联合依达拉奉的临床治疗效果。方法 76例急性脑梗死患者,数字法随机分为对照组和研究组,每组38例。两组患者首先均接受降压、降糖、纠正电解质等常规治疗,对照组采用依达拉奉治疗,研究组在对照组基础上联合尤瑞克林,对比两组患者临床疗效。结果研究组治疗总有效率为92.1%,明显高于对照组的76.3%,差异具有统计学意义(χ~2=6.359,P=0.032<0.05)。治疗后两组患者日常生活活动能力(ADL)评分、美国国立卫生院神经功能缺损评分(NIHSS)对比,差异具有统计学意义(P<0.05)。结论急性脑梗死治疗中尤瑞克林联合依达拉奉的临床治疗效果明显,可明显提高患者的生活能力,适合于临床推广。
Objective To analyze the clinical effect of uracil combined with edaravone in the treatment of acute cerebral infarction. Methods 76 patients with acute cerebral infarction, digital method were randomly divided into control group and study group, 38 cases in each group. The two groups were treated with conventional therapy such as antihypertensive, hypoglycemic and correct electrolytes. The control group was treated with edaravone. The study group was treated with irinocuin on the basis of the control group, and the clinical efficacy was compared between the two groups. Results The total effective rate of study group was 92.1%, which was significantly higher than that of the control group (76.3%). The difference was statistically significant (χ ~ 2 = 6.359, P = 0.032 <0.05). After treatment, the activities of daily living (ADL) score of the two groups of patients and the National Institutes of Health neurological deficit score (NIHSS), the difference was statistically significant (P <0.05). Conclusion The clinical effect of uracil combined with edaravone in the treatment of acute cerebral infarction is obvious, which can obviously improve the living ability of patients and is suitable for clinical promotion.